Rising Ozone Levels Associated with ARDS
ARDS is a life-threatening inflammatory lung illness in which patients fail to obtain enough oxygen to the lungs. While previous research has shown a clear association between cigarette smoke and ARDS, the current study by Lorraine Ware, MD, of Vanderbilt University School of Medicine, and colleagues is the first to demonstrate a risk related to ozone.
The researchers analysed exposure using a heterogenous group of 1,558 critically ill patients from the Validating Acute Lung Injury Biomarkers for Diagnosis cohort. Subjects enrolled in 2006-2012 were included if a residential address was available, they lived within 50 km of at least one air quality monitor and had an ARDS risk factor (ie, trauma, smoking, alcohol use).
The research team found that as long-term ozone exposure increased, so did rates of ARDS, which developed in 563 patients. The association between ARDS risk and ozone exposure was greatest among trauma patients (n=552). In addition, “Ozone was significantly associated with ARDS only in current smokers and not in non-smokers,” the authors note.
“The generalisability of this most recent study is enhanced given the large and heterogenous cohort we had at our disposal,” Dr. Ware points out. “However, we acknowledge that future studies need to replicate the findings in more diverse geographic samples so that we may more confidently recommend guidelines for reducing ozone exposure and ARDS risk among this vulnerable group of patients.”
As the potentially harmful health consequences of ozone exposure continue to draw more concern, the demand for more research will likely increase because this study as well as another study on ozone and mortality appearing in the same issue of the AJRCCM suggest the need for a stricter ozone standard.
Source: American Thoracic Society
Image credit: Thinkstockphotos
Published on : Thu, 14 Jan 2016
Stay informed at every point of care In compliance with out-of-hospital patient transport standards such as EN1789, EN13718-1, IEC60601-1-12 and U.S. military standards, N1 is a highly competent solution for various out-of-hospital transport settings...
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...
The fully featured ICU ventilator, HAMILTON-MR1, guarantees uncompromised continuous ventilation care from the ICU to the MRI scanner and back. Its reliability and high performance, with advanced lung-protective strategies and patient-adaptive modes,...
User experience enhanced by leading technologies With state-of-the-art screen technology, BeneVision N-Series patient monitors deliver clear, multi-color, wide-format displays for users to capture and review information at a glance. With...